News
- 2023-03-23
BriSTAR Immunotech to Present its Novel Cell Therapy for Acute Myeloid Leukemia at the 2023 AACR Annual Meeting
March 23, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 14-19, 2023 in Orlando, Florida.
- 2023-01-31
BriSTAR Immunotech to Present at the BIO CEO & Investor Conference
January 31, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today that its Chief Executive Officer, James Pan, Ph.D., will be presenting at the 25th BIO CEO & Investor Conference. The conference will take place at the New York Marriott Marquis during February 6-9, 2023.
- 2023-01-19
BriSTAR Immunotech To Present its Novel Cell Therapy for Acute Myeloid Leukemia at the AACR Special Conference on AML and MDS
January 19, 2023 - TORONTO & BEIJING -- BriSTAR Immunotech, a clinical-stage cell therapy company, announced today it will showcase its T-cell receptors (TCR) and antigen receptor (STAR)-T cell therapy technology platform at the American Association for Cancer Research (AACR) special conference on acute myeloid leukemia and myelodysplastic syndrome, taking place January 23-25, 2023, in Austin, Texas.
About us
Our team at BriSTAR Immunotech is dedicated to the development and commercialization of innovative T cell immunotherapy products for the treatment of cancer and viral infections with urgent unmet medical needs.
We leverage our proprietary STAR-T platform to engineer next-generation T cell therapies for treating hematological malignancies and solid tumors. The STAR-T platform combines the advantages of CAR-T (Chimeric Antigen Receptor T-Cell immunotherapy) and TCR-T (T Cell Receptor T-cell immunotherapy) to produce mono- or bi-specific T cell therapies.
The promising antitumor actions of STAR-T cell therapies include better antigen sensitivity and stronger tumor infiltration. These properties are critical for achieving better responses in cancer patients, especially in treating solid tumors.
![](/upload/img01.jpg)
-
2018
Established In
-
60+
Employees
-
3500m²
37,600 sq.ft. R&D center
-
8+
Important Publications
Platform
![](/upload/img02.png)
![](/upload/img03.png)
Technology
Manufacturing
Pioneering Technology Platform
STAR-T & enTCR-T
![](/upload/img04.png)
![](/upload/img05.png)
Technology
Pioneering Technology Platform
STAR-T & enTCR-T
Manufacturing
![](/upload/img06.jpg)
Pipeline
Our product pipeline is designed to address urgent unmet clinical needs in hematologic malignancies and solid tumors.
READ MOREStay In Touch With BriSTAR Immunotech
Send our team your questions | Sign up to receive news updates